January 25, 2019 11:16 AM ESTUpdated May 26, 08:22 PM
Cell/Gene Tx

A stem cell ther­a­py preps de­but in Japan­ese mar­ket to the dis­may of US re­searchers

Amber Tong

As Japan ap­proves a stem cell treat­ment for spinal cord in­juries in a land­mark — if lit­tle no­ticed — de­ci­sion, ex­perts around the world have voiced con­cerns …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times